In vivo function of MC proteases, based on MC protease-deficient mouse strains
MC protease deficiency . | Phenotype . | Implicated mechanism . | Reference . |
---|---|---|---|
mMCP-4 | Less severe collagen induced arthritis | Effects on anticollagen II IgG generation, inflammation | 35 |
Less development of AAAs | Effects on inflammation, apoptosis, elastin degradation | 36 | |
Increased susceptibility to allergic airway inflammation | Effects on smooth muscle cells, inflammation | 37 | |
Tissue accumulation of ECM | Defective fibronectin and proMMP-9 processing | 38,39 | |
Reduced basal intestinal permeability | Effects on epithelial cell migration | 40 | |
mMCP-5 | Decreased ischemia reperfusion injury | Unknown | 41 |
mMCP-1 | Increased susceptibility to T spiralis infection | Promotion of capillary permeability; degradation of cell-cell junctions | 42,–44 |
mMCP-6 | Less severe passively induced arthritis (K/BxN model) | Effect on expression of the neutrophil chemotactic factors CXCL1/KC, CXCL5/LIX, and CXCL8/IL-8; effect on aggrecan degradation | 34 |
Nonadequate response to T spiralis infection | Effect on eosinophil recruitment | 24 | |
Increased susceptibility to K pneumoniae infection | Effect on neutrophil recruitment and production of inflammatory cytokines | 25 | |
Less severe passively induced arthritis (methyl-BSA/IL-1β model) | Unknown | 33 | |
mMCP-7* | Less severe passively induced arthritis (methyl-BSA/IL-1β model) | Unknown | 33 |
MC-CPA | Increased susceptibility to snake poison envenomation | Degradation of sarafotoxins | 45,46 † |
Defective granule staining | Effects on serglycin proteoglycan solubility | 47 |
MC protease deficiency . | Phenotype . | Implicated mechanism . | Reference . |
---|---|---|---|
mMCP-4 | Less severe collagen induced arthritis | Effects on anticollagen II IgG generation, inflammation | 35 |
Less development of AAAs | Effects on inflammation, apoptosis, elastin degradation | 36 | |
Increased susceptibility to allergic airway inflammation | Effects on smooth muscle cells, inflammation | 37 | |
Tissue accumulation of ECM | Defective fibronectin and proMMP-9 processing | 38,39 | |
Reduced basal intestinal permeability | Effects on epithelial cell migration | 40 | |
mMCP-5 | Decreased ischemia reperfusion injury | Unknown | 41 |
mMCP-1 | Increased susceptibility to T spiralis infection | Promotion of capillary permeability; degradation of cell-cell junctions | 42,–44 |
mMCP-6 | Less severe passively induced arthritis (K/BxN model) | Effect on expression of the neutrophil chemotactic factors CXCL1/KC, CXCL5/LIX, and CXCL8/IL-8; effect on aggrecan degradation | 34 |
Nonadequate response to T spiralis infection | Effect on eosinophil recruitment | 24 | |
Increased susceptibility to K pneumoniae infection | Effect on neutrophil recruitment and production of inflammatory cytokines | 25 | |
Less severe passively induced arthritis (methyl-BSA/IL-1β model) | Unknown | 33 | |
mMCP-7* | Less severe passively induced arthritis (methyl-BSA/IL-1β model) | Unknown | 33 |
MC-CPA | Increased susceptibility to snake poison envenomation | Degradation of sarafotoxins | 45,46 † |
Defective granule staining | Effects on serglycin proteoglycan solubility | 47 |